Subject Index

Acitretin, skin cancer chemoprevention 66
Actinic keratosis (AK)
  immunosuppression agent selection for prevention 44
  management 60
  progression prevention 187, 188
  screening in transplant candidates 58
topical therapy for prevention 61
Acute generalized exanthematic pustulosis, drug hypersensitivity reaction 157
Adnexal tumors, transplant patients 26
AFX, see Atypical fibroxanthoma
AK, see Actinic keratosis
Alefacept, immunosuppression agent prospects 76, 77
Anaphylaxis, drug hypersensitivity reaction 156
Angioedema, drug hypersensitivity reaction 154
Anti-thymocyte globulin (ATG), immunosuppression and side effects 42, 43
ATG, see Anti-thymocyte globulin
Atypical fibroxanthoma (AFX), transplant patients 30
Avascular bone necrosis, hematopoietic stem cell transplantation late effect 142, 143
Azathioprine
  metabolism 40
  photosensitzation 41, 65
  squamous cell carcinoma risks 6, 40
Basal cell carcinoma (BCC)
  basosquamous carcinoma 22, 23
  epidemiology in organ transplantation 22
  genetics 23
  histology 22, 23
  management 23, 24, 63
  screening in transplant candidates 58
BCC, see Basal cell carcinoma
BD, see Bowen's disease
Belatacept, immunosuppression agent prospects 76
Belimumab, immunosuppression agent prospects 75
Bone marrow transplantation, see Hematopoietic stem cell transplantation
Bortezomibe, immunosuppression agent prospects 77
Bowen's disease (BD)
  management 60
  screening in transplant candidates 58
Calcineurin inhibitors, see Cyclosporin A; Tacrolimus
Candida albicans, skin infection with immunosuppression 14
Capecitabine, skin cancer chemoprevention 66, 67
Cardiovascular disease (CVD), hematopoietic stem cell transplantation late effect 141, 142
Caries, hematopoietic stem cell transplantation late effect 140
Chronic kidney disease, hematopoietic stem cell transplantation late effect 142
Corticosteroids, see Glucocorticoids
CVD, see Cardiovascular disease
Cyclosporin A
  cutaneous side effects 40
  graft-versus-host disease management 108, 109
  mechanism of immunosuppression 39, 40
  sparing studies 73
  squamous cell carcinoma risks 6
Diclofenac, topical therapy for squamous cell carcinoma prevention 61

Drug hypersensitivity reactions, hematopoietic stem cell transplantation
clinical manifestations
  acute generalized exanthematic pustulosis 157
  anaphylaxis 156
  angioedema 154
  drug hypersensitivity syndrome 157, 158
erythema exudativum multiforme 158
erythema nodosum 160, 161
fever 154
general symptoms 154
interstitial granulomatous drug reaction 160
lichen planus 160
maculopapular exanthema 156, 157
psoriasis 159, 160
Stevens-Johnson syndrome 158
stomatitis 159
Sweet’s syndrome 161
table 155, 156
toxic epidermal necrolysis 158, 159
urticaria 154
vasculitis 159
diagnosis 161, 162
differential diagnosis
  graft-versus-host disease 153
  infectious exanthema 151, 152
eliciting drugs 161
overview 150, 151

ECP, see Extracorporeal photophoresis
EEM, see Erythema exudativum multiforme
ELR, see Eruption of lymphocyte recovery
Epidermodysplasia verruciformis (EV)
  beta human papillomavirus role 50
genetics 50, 51
Eruption of lymphocyte recovery (ELR), drug hypersensitivity reaction differential diagnosis 153
Erythema exudativum multiforme (EEM), drug hypersensitivity reaction 158
Erythema nodosum, drug hypersensitivity reaction 160, 161
EV, see Epidermodysplasia verruciformis
EVER proteins, function 12, 51
Extracorporeal photophoresis (ECP), chronic graft-versus-host disease management
  adult patient outcomes 123–125
  mechanism of action 122, 123
  pediatric patient outcomes 126–128
  sclerotic-type disease outcomes 125, 126
  steroid-sparing effect in hematopoietic stem cell transplantation 128
technique 123

Fever, drug hypersensitivity reaction 154
Filaggrin, barrier function 10

Glucocorticoids
  avoidance or withdrawal 72
  cutaneous side effects 39
  graft-versus-host disease management
    systemic therapy 108
    topical therapy 107, 108
  mechanism of immunosuppression 39

Graft-versus-host disease (GVHD)
cellular therapy 168, 169
drug hypersensitivity reaction differential diagnosis 153
late organ dysfunction role 142, 143
National Institutes of Health consensus project 166
GVHD, see Graft-versus-host disease

HCQ, see Hydroxychloroquine
Health consensus project 166
  acute disease 102, 103
  acute disease and T cell populations
    naive T cells 94
    regulatory T cells 94
    Th17 cells 94
  changing concepts 88, 89
  chronic disease 84, 91, 96, 97, 103–107, 165–167
  chronic graft-versus-host disease
    consortium 166, 167
    clinical significance 165, 166
    management
      extracorporeal photophoresis for chronic disease
        adult patient outcomes 123–125
        mechanism of action 122, 123
        pediatric patient outcomes 126–128
        sclerotic-type disease outcomes 125, 126
        steroid-sparing effect in hematopoietic stem cell transplantation 128
technique 123
mesenchymal stem cell infusion 111, 112
supportive care 112
systemic therapy
cyclosporine 108, 109
glucocorticoids 108
hydroxychloroquine 109, 110
imatinib mesylate 110
mycophenolate mofetil 109
retinoids 111
rituximab 110
sirolimus 109
tacrolimus 108, 109
thalidomide 111
topical therapy 107, 108
ultraviolet A1 phototherapy for chronic disease
mechanism of action 120
outcomes 118, 119
overview 117, 118
side effects 120, 121
technique 121, 122
pathogenesis
effector stage 95, 96
immune response priming 92
overview 92
T cell activation and costimulation 92, 93
T cell trafficking 95
requirements 83, 84
Hematopoietic stem cell transplantation (HSCT)
drug hypersensitivity reactions, see Drug hypersensitivity reactions, hematopoietic stem cell transplantation
graft-versus-host disease, see also Graft-versus-host disease
changing concepts 88, 89
chronic disease 84
requirements 83, 84
historical perspective 82–87
indications 85, 86
late effects
direct effects of transplant procedure 138, 139
graft-versus-host disease role in late organ dysfunction 142, 143
importance of study 145, 146
overview 133–137
pattern changes over time 137, 138
reduced intensity conditioning in prevention 143–145
secondary and tertiary events 139–142
macroeconomic aspects 87
prospects 89
techniques 87
trends 167, 168
HHV-6, see Human herpesvirus 6
HHV-8, see Human herpesvirus 8
HIV, see Human immunodeficiency virus
HPV, see Human papillomavirus
HSCT, see Hematopoietic stem cell transplantation
Human herpesvirus 6 (HHV-6), drug hypersensitivity reaction differential diagnosis 151
Human herpesvirus 8 (HHV-8), Kaposi sarcoma role 28, 29
Human immunodeficiency virus (HIV) skin problems 14–17
squamous cell carcinoma role 21
Human papillomavirus (HPV) beta HPV and epidermodysplasia verruciformis 50
epidemiology in organ transplantation 3
squamous cell carcinoma association 52, 53
Hydroxychloroquine (HCQ), graft-versus-host disease management 109, 110
Imatinib mesylate, graft-versus-host disease management 110
Imiquinod, topical therapy for squamous cell carcinoma prevention 61
Immunosuppression, see also specific drugs
drug selection for skin lesion prevention actinic keratosis 44
Kaposi sarcoma 45
melanoma 45
Merkel cell carcinoma 56
squamous cell carcinoma 44, 45
overview of agents 39–43
pretransplant risk assessment 77, 78
principles 37–39
prospects 74
ultraviolet radiation
immunosuppression 175
Infertility, hematopoietic stem cell transplantation late effect 138, 139
Inflammation, skin
drug reactions in solid organ transplantation 3
immunosuppression effects 2, 3
Isotretinoin, skin cancer chemoprevention 66

Kaposi sarcoma (KS)
histology 28, 29
human herpesvirus 8 role 28, 29
human immunodeficiency virus patients 15, 17
immunosuppression agent selection for prevention 45, 64
management 63, 64
transplant patients 11, 14, 28–30
KS, see Kaposi sarcoma

Langerin, function 10
Lichen planus, drug hypersensitivity reaction 160
Lymphoma, posttransplant lymphoproliferative disorders 30, 31

Maculopapular exanthema, drug hypersensitivity reaction 156, 157
Malignant melanoma, see Melanoma
Mammalian target of rapamycin (mTOR), inhibitors as immunosuppressants 41, 42, 44, 65
MCC, see Merkel cell carcinoma
Melanoma
epidemiology in organ transplantation 26, 27
histology 27
immunosuppression agent selection for prevention 45
management 63
prognosis 27
Merkel cell carcinoma (MCC)
epidemiology in organ transplantation 24
histology 24, 25
immunosuppression agent selection for prevention 56
management 64
markers 24
metastasis 26
viral causation 26
Mesenchymal stem cell (MSC), graft-versus-host disease management 111, 112
MMF, see Mycophenolate mofetil
MSC, see Mesenchymal stem cell
mTOR, see Mammalian target of rapamycin
Mycophenolate mofetil (MMF) cutaneous side effects 41

Osteoprosis, hematopoietic stem cell transplantation late effect 139, 140

Photodynamic therapy, squamous cell carcinoma prevention 61
Photoprotection
clothing 76
environmental photoprotection 175, 176
sunscreen controversies 180
efficacy 181
inorganic agents 177
organic agents 177, 178
quality factors 180
safety absorption and endocrine effects 182, 183
adverse reactions 181, 182
vitamin D deficiency 182
sun protection factor 183, 184
ultraviolet absorbers 176–179
vehicle selection and formulation 179, 180
water resistance 184, 185
transplant recipient skin cancer prevention educational and behavioral aspects 189, 190
overview 58, 59, 171–173
premalignant lesion progression prevention 187, 188
primary prevention 187
second primary tumor prevention 188, 189
ultraviolet radiation biological effects 174
classification 173, 174
immunosuppression 175
lifetime ultraviolet dose 185, 186
Pityrosporum folliculitis 3
Posttransplant lymphoproliferative disorders (PTLD), skin manifestations 30, 31
Psoriasis, drug hypersensitivity reaction 159, 160
PTLD, see Posttransplant lymphoproliferative disorders
Reduced intensity conditioning (RIC), hematopoietic stem cell transplantation late effect prevention 143–145
Retinoids, see also specific retinoids
graft-versus-host disease management 111
RIC, see Reduced intensity conditioning
Rituximab
graft-versus-host disease management 110
immunosuppression agent prospects 74, 75
Sarcoma, transplant patients 30
SCC, see Squamous cell carcinoma
Sirolimus, graft-versus-host disease management 109
SJS, see Stevens-Johnson syndrome
Skin cancer, see Adnexal tumors; Basal cell carcinoma; Kaposi sarcoma; Lymphoma; Melanoma; Merkel cell carcinoma; Squamous cell carcinoma
Squamous cell carcinoma (SCC)
basosquamous carcinoma 22, 23
chemoprevention 66, 67
high-risk squamous cell carcinoma 62, 63
histology 19–21
human papillomavirus association 52, 53
immunosuppression agent selection for prevention 44, 45, 64, 65
immunosuppression effects 4–6
integrated care 67
management 21, 22, 44, 59–61
pathogenesis 21
photodamage in organ transplantation recipients 3, 4, 6
precursors 19, 20
screening in transplant candidates 58
topical therapy for prevention 61
variants 21
Stevens-Johnson syndrome (SJS), drug hypersensitivity reaction 158
Stomatitis, drug hypersensitivity reaction 159
Sun protection factor, see Photoprotection
Sunscreen, see Photoprotection
Sweet's syndrome, drug hypersensitivity reaction 161
T cell, graft-versus-host disease activation and costimulation 92, 93
acute disease T cell populations
naive T cells 94
regulatory T cells 94
Th17 cells 94
effecter stage 95, 96
trafficking 95
Tacrolimus
cutaneous side effects 40
graft-versus-host disease management 108, 109
mechanism of immunosuppression 39, 40
squamous cell carcinoma risks 6
TEN, see Toxic epidermal necrolysis
Thalidomide, graft-versus-host disease management 111
Toxic epidermal necrolysis (TEN), drug hypersensitivity reaction 158, 159
Ultraviolet A1 phototherapy, chronic graft-versus-host disease management
mechanism of action 120
outcomes 118, 119
overview 117, 118
side effects 120, 121
technique 121, 122
Ultraviolet protection, see Photoprotection
Urticaria, drug hypersensitivity reaction 154
Vasculitis, drug hypersensitivity reaction 159
Vitamin D
status in transplant patients 59
sunscreen and deficiency 182
Voriconazole, skin cancer risks 65